A method for preparing (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylic acid

(S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptan-2-carboxylic acid was prepared by esterification, cyclization, N-acylation and hydrolysis reactions, which solved the problems of high cost of chiral propylene oxide and unsafe palladium-catalyzed reduction in the prior art, and realized economical and efficient industrial production.

CN123106569APending Publication Date: 2026-11-17JIANGXI SYNERGY PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611411190.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-11
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing synthetic route for brisocarte involves chiral propylene oxide, which is expensive and has low safety, making it unsuitable for large-scale production. Palladium-catalyzed hydrogenation reduction reactions also pose safety risks.

Method used

The esterification reaction was carried out with (S)-isoserine using an acyl chloride reagent, followed by a cyclization reaction with 1,3-dibromopropane, and then an N-acylation reaction with di-tert-butyl dicarbonate. Finally, the (S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylic acid was obtained by hydrolysis.

Benefits of technology

It achieves readily available raw materials, high atom economy, low cost, high safety, suitability for industrial production, mild reaction conditions, high yield, and simple post-processing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106569A_ABST
    Figure CN123106569A_ABST
Patent Text Reader

Abstract

This invention provides a method for preparing (S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylic acid, belonging to the field of pharmaceutical synthesis chemistry. In this invention, (S)-isoserine is esterified with methanol under the action of an acyl chloride reagent to obtain compound B1; compound B1 is cyclized with 1,3-dibromopropane in an organic solvent under the action of a first basic reagent to obtain compound B2; compound B2 is N-acylated with di-tert-butyl dicarbonate in an organic solvent under the action of a second basic reagent to obtain compound B3; and compound B3 is hydrolyzed in an organic solvent under the action of a third basic reagent to obtain compound B. This invention utilizes readily available raw materials, has high atom economy, produces little chemical waste, and is low in cost; it eliminates the need for palladium-carbon hydrogenation reduction, ensuring high safety; the reaction conditions are mild, the yield is high, and the post-processing is simple, making it suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical synthesis chemistry, and in particular to a method for preparing (S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylic acid. Background Technology

[0002] Brisocatib is indicated for the treatment of noncystic fibrotic bronchiectasis in adults and children aged 12 years and older. It primarily works by inhibiting dipeptidyl peptidase-1 (DPP1) to reduce the activation of neutrophil serine proteases, thereby inhibiting the airway inflammatory chain response at its source and reducing the risk of disease exacerbation. It is the first and only drug approved by the FDA for the treatment of this disease, marking the arrival of the first targeted therapy in this field. The synthetic route of brensocatib as reported in relevant patents is shown below: , Among them, (S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylic acid (compound B, CAS No.: 1273567-44-4) is an important intermediate of brisocarte. Compound B is a seven-membered ring compound with one chiral carbon atom, making its synthesis difficult. Three synthetic routes have been reported, all derived from chiral propylene oxide compounds, as shown in routes 1-3: Route 1: , Route 2: , Route 3: .

[0003] The chiral propylene oxide used in the above routes is expensive, and all of them require palladium-catalyzed hydrogenation reduction reactions. Route 3 also requires the use of highly toxic borane gas, which has low safety and is not suitable for large-scale production. Summary of the Invention

[0004] In view of this, the object of the present invention is to provide a method for preparing (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylic acid. The preparation method provided by the present invention has a simple route, strong atom economy, readily available raw materials, and does not require hydrogenation reduction, thus having high economic value and being particularly suitable for industrial production.

[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a method for preparing (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptan-2-carboxylic acid, comprising the following steps: (S)-isoserine was esterified with methanol in the presence of an acyl chloride to give compound B1. Under the action of a first alkaline reagent, compound B1 was subjected to a cyclization reaction with 1,3-dibromopropane in an organic solvent to obtain compound B2; In the presence of a second alkaline reagent, compound B2 is reacted with di-tert-butyl dicarbonate in an organic solvent to undergo an N-acylation reaction to obtain compound B3; Under the action of a third basic reagent, compound B3 was hydrolyzed in an organic solvent to obtain (S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylic acid; The structural formulas of compounds B1, B2 and B3 are shown below: , , .

[0006] Preferably, the molar equivalent ratio of the acyl chloride reagent to (S)-isoserine is 1.2~1.8:1.

[0007] Preferably, the molar equivalent ratio of the first alkaline reagent to compound B1 is 3.0~5.0:1.

[0008] Preferably, the molar equivalent ratio of 1,3-dibromopropane to compound B1 is 1.2 to 1.5:1.

[0009] Preferably, the molar equivalent ratio of the second alkaline reagent to compound B2 is 1.2 to 1.5:1.

[0010] Preferably, the N-acylation reaction is carried out at a temperature of 0~30℃ for 6~12h.

[0011] Preferably, the molar equivalent ratio of the third basic reagent to compound B3 is 0.57~1.0:1.

[0012] Preferably, the organic solvent used in the hydrolysis reaction includes one or more of tetrahydrofuran, acetonitrile, methanol, ethanol, isopropanol, acetone, and 1,4-dioxane.

[0013] Preferably, the cyclization reaction is carried out at a temperature of 25-60°C for 10-20 hours.

[0014] Preferably, the hydrolysis reaction is carried out at a temperature of 50-80°C for 6-12 hours.

[0015] This invention provides a method for preparing (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylic acid, comprising the following steps: esterifying (S)-isoserine with methanol under the action of an acyl chloride reagent to obtain compound B1; cyclizing compound B1 with 1,3-dibromopropane in an organic solvent under the action of a first basic reagent to obtain compound B2; N-acylation of compound B2 with di-tert-butyl dicarbonate in an organic solvent under the action of a second basic reagent to obtain compound B3; and hydrolyzing compound B3 in an organic solvent under the action of a third basic reagent to obtain the (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylic acid.

[0016] Compared with the prior art, the beneficial effects of the present invention are as follows: 1. Raw materials are readily available, atom economy is high, chemical waste is low, and cost is low.

[0017] 2. No palladium carbon hydrogenation reduction is required, resulting in high safety.

[0018] 3. The reaction conditions are mild, the yield is high, and the post-processing is simple, making it particularly suitable for industrial production. Attached Figure Description

[0019] Figure 1 The 1H NMR spectrum of compound B1 prepared in Example 1 of this invention; Figure 2 The 1H NMR spectrum of compound B2 prepared in Example 3 of this invention; Figure 3 The 1H NMR spectrum of compound B3 prepared in Example 5 of this invention; Figure 4 The above is the 1H NMR spectrum of compound B prepared in Example 7 of this invention. Detailed Implementation

[0020] This invention provides a method for preparing (S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylic acid (compound B), comprising the following steps: (S)-isoserine was esterified with methanol in the presence of an acyl chloride to give compound B1. Under the action of a first alkaline reagent, compound B1 was subjected to a cyclization reaction with 1,3-dibromopropane in an organic solvent to obtain compound B2; In the presence of a second alkaline reagent, compound B2 is reacted with di-tert-butyl dicarbonate in an organic solvent to undergo an N-acylation reaction to obtain compound B3; Under the action of a third basic reagent, compound B3 was hydrolyzed in an organic solvent to obtain (S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylic acid; The structural formulas of compounds B1, B2 and B3 are shown below: , , .

[0021] In this invention, the flowchart of the preparation method is shown in Formula 1: Formula 1.

[0022] Unless otherwise specified, all raw materials used in this invention are commercially available products in the field.

[0023] In this invention, (S)-isoserine is esterified with methanol under the action of an acyl chloride reagent to obtain compound B1 ([(S)-2-hydroxy-3-methoxy-3-oxopropyl]ammonium chloride).

[0024] In this invention, the acyl chloride reagent preferably includes one or more of thionyl chloride, oxalyl chloride, phosphorus trichloride, phosphorus pentachloride and triphosgene, and more preferably thionyl chloride.

[0025] In this invention, the molar equivalent ratio of the acyl chloride reagent to (S)-isoserine is preferably 1.2 to 1.8:1.

[0026] In this invention, the preferred ratio of (S)-isoserine to methanol is 200g:1~1.5L.

[0027] In this invention, the temperature of the esterification reaction is preferably 20~45℃, specifically 25 or 45℃, and the time is preferably 6~12h, specifically 8 or 10h.

[0028] In this invention, the (S)-isoserine and methanol are added to a reaction vessel, the acyl chloride reagent is added dropwise under an ice-water bath, and the esterification reaction is carried out by heating.

[0029] After obtaining compound B1, the present invention further describes the cyclization reaction of compound B1 with 1,3-dibromopropane in an organic solvent under the action of a first alkaline reagent to obtain compound B2 ((S)-1,4-oxazetane-2-carboxylic acid methyl ester).

[0030] In this invention, the first alkaline reagent preferably includes one or more of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) and sodium methoxide, more preferably potassium carbonate or potassium hydroxide.

[0031] In this invention, the molar equivalent ratio of the first alkaline reagent to compound B1 is preferably 3.0 to 5.0:1.

[0032] In this invention, the molar equivalent ratio of 1,3-dibromopropane and compound B1 is preferably 1.2 to 1.5:1.

[0033] In this invention, the organic solvent used in the cyclization reaction preferably includes one or more of toluene, acetone, 1,4-dioxane, acetonitrile, N,N-dimethylformamide (DMF), and tetrahydrofuran, more preferably 1,4-dioxane or acetonitrile.

[0034] In this invention, the cyclization reaction is preferably carried out at a temperature of 25-60°C, specifically 35 or 50°C, and the reaction time is preferably carried out at a time of 10-20 hours, specifically 12 or 26 hours.

[0035] In this invention, the compound B1 and the first basic reagent are added to a reaction vessel, followed by the organic solvent, and then the 1,3-dibromopropane is added dropwise with stirring to carry out the cyclization reaction.

[0036] After the cyclization reaction is completed, the resulting mixture is preferably filtered at room temperature, and the filtrate is evaporated under reduced pressure to obtain a yellow colloidal compound, which is methyl (S)-1,4-oxazetane-2-carboxylate.

[0037] After obtaining compound B2, the present invention further describes the N-acylation reaction of compound B2 with di-tert-butyl dicarbonate in an organic solvent under the action of a second alkaline reagent to obtain compound B3 ((S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylate methyl ester).

[0038] In this invention, the molar equivalent ratio of the second alkaline reagent to compound B2 is preferably 1.2 to 1.5:1.

[0039] In this invention, the mass ratio of compound B2 to di-tert-butyl dicarbonate is preferably 200:411.3~548.4.

[0040] In this invention, the second alkaline reagent preferably includes one or more of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, and sodium ethoxide, and more preferably sodium hydroxide or potassium hydroxide.

[0041] In this invention, the second alkaline reagent is preferably used in the form of an aqueous solution of an alkaline reagent.

[0042] In this invention, the preferred temperature for the N-acylation reaction is 0~30°C, and the preferred time is 6~12h. Under the temperature conditions of the N-acylation reaction, the acylation rate of the amino group of compound B2 with di-tert-butyl dicarbonate is much higher than the hydrolysis rate of methyl ester. Therefore, the N-acylated product B3 can be obtained with high selectivity in an aqueous alkaline system (alkaline reagent aqueous solution) without the need for anhydrous conditions, which simplifies the operation and reduces costs.

[0043] In this invention, the organic solvent used in the N-acylation reaction preferably includes one or more of tetrahydrofuran, acetonitrile, acetone and 1,4-dioxane, preferably tetrahydrofuran or acetonitrile.

[0044] In this invention, the compound B2, the second basic reagent, water, and an organic solvent are added to a reaction vessel, stirred at room temperature until clear, and then the di-tert-butyl dicarbonate is added to carry out the N-acylation reaction.

[0045] After the N-acylation reaction is completed, the resulting mixture is preferably diluted with water, the pH is adjusted to 2.0 with 2M hydrochloric acid, the aqueous phase is extracted with ethyl acetate, and then the solvent is removed by rotary evaporation to obtain a pale yellow solid compound B3.

[0046] After obtaining compound B3, the present invention hydrolyzes compound B3 in an organic solvent under the action of a third basic reagent to obtain (S)-4-(tert-butoxycarbonyl)-1,4-oxazine-heptane-2-carboxylic acid.

[0047] In this invention, the molar equivalent ratio of the third basic reagent and compound B3 is preferably 0.57~1.0:1.

[0048] In this invention, the organic solvent used in the hydrolysis reaction preferably includes one or more of tetrahydrofuran, acetonitrile, methanol, ethanol, isopropanol, acetone and 1,4-dioxane, more preferably methanol or acetonitrile.

[0049] In this invention, the temperature of the hydrolysis reaction is preferably 50~80℃, specifically 60 or 70℃, and the time is preferably 6~12h, specifically 7 or 10h.

[0050] In this invention, the preferred ratio of compound B3 to organic solvent is 100g:1L.

[0051] In this invention, the third alkaline reagent is preferably used in the form of a third alkaline reagent solution, and the concentration of the third alkaline reagent solution is preferably 77.25 or 46.25 g / L.

[0052] After the hydrolysis reaction is completed, the obtained product is preferably cooled to room temperature, the mixture is extracted with diethyl ether, the combined organic solutions are washed with brine, dried with sodium sulfate, and concentrated under vacuum to obtain a white solid crude product. The crude product is then recrystallized from hexane and dichloromethane (preferably in a volume ratio of 0.4:1) to obtain a white solid, which is the (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylic acid (compound B).

[0053] The technical solutions of this invention will be clearly and completely described below with reference to the embodiments thereof. Obviously, the described embodiments are only a part of the embodiments of this invention, and not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort are within the scope of protection of this invention.

[0054] Example 1 The principle for preparing compound B1 is shown in Formula 2: Formula 2; (S)-Isoserine (200 g) and methanol (1 L) were added to a reaction vessel, and 400 g of thionyl chloride was added dropwise under an ice-water bath. The mixture was heated to 25 °C and stirred for 10 h. After the reaction was completed, the organic layer was evaporated to dryness, and acetonitrile (400 mL) was added. The mixture was heated and stirred until a slurry was formed. After centrifugation, 285.9 g of a white compound, [(S)-2-hydroxy-3-methoxy-3-oxomylidenepropyl]ammonium chloride (compound B1), was obtained, with a yield of 96.8%. 1 H NMR (400 MHz, DMSO- D 6 ) δ 8.31 (s, 3H), 4.42-4.38 (dd, J = 8.7, 3.7 Hz,1H), 3.64 (s, 3H), 3.08-3.04 (dd, J = 13.0, 3.8 Hz, 1H), 2.89-2.84 (dd, J = 13.0, 8.7 Hz, 1H).

[0055] Figure 1 The image shows the hydrogen nuclear magnetic resonance spectrum of compound B1 prepared in Example 1 of this invention.

[0056] Example 2 Preparation of compound B1: (S)-Isoserine (200 g) and methanol (1.5 L) were added to a reaction vessel, and sulfoxide (280 g) was added dropwise under an ice-water bath. The mixture was heated to 45 °C and stirred for 8 h. After the reaction was completed, the organic layer was evaporated to dryness, and acetonitrile (1 L) was added. The mixture was heated and stirred until a slurry was formed. After centrifugation, 280.3 g of a white compound, [(S)-2-hydroxy-3-methoxy-3-oxomylidenepropyl]ammonium chloride (compound B1), was obtained, with a yield of 94.9%.

[0057] Example 3 The principle for preparing compound B2 is shown in Formula 3: Formula 3; B1 (200 g) and potassium carbonate (534.9 g) were added to a reaction vessel, and 2 L of acetonitrile was added at 35 °C and stirred for 20 min. Subsequently, 1,3-dibromopropane (312.54 g) was added dropwise and stirred for 16 h. After the reaction was completed, the mixture was filtered at room temperature. The filtrate was evaporated under reduced pressure to give 175.3 g of a yellow gelatinous compound, methyl (S)-1,4-oxazacycloheptane-2-carboxylate (compound B2), with a yield of 85.4%. 1 H NMR (400 MHz, DMSO- D 6 ) δ 5.72 (s, 1H), 4.32-4.29 (dd, J = 7.5,5.2 Hz, 1H), 4.16-4.13 (m, 2H), 3.62 (s, 3H), 3.58-3.53 (dd, J = 13.8, 5.2 Hz,1H), 3.46-3.28 (m, 2H), 3.27-3.21 (dd, J = 13.9, 7.6 Hz, 1H), 1.93-1.87 (m,2H).

[0058] Figure 2 The image shows the hydrogen nuclear magnetic resonance spectrum of compound B2 prepared in Example 3 of this invention.

[0059] Example 4 Preparation of compound B2: B1 (200 g) and potassium hydroxide (361.9 g) were added to a reaction vessel, and 1 L of 1,4-dioxane was added at 50 °C and stirred for 20 min. Subsequently, 1,3-dibromopropane (390.7 g) was added dropwise and stirred for 12 h. After the reaction was completed, the mixture was filtered at room temperature. The filtrate was evaporated under reduced pressure to give 179.1 g of a yellow gelatinous compound, methyl (S)-1,4-oxazetane-2-carboxylate (compound B2), with a yield of 87.2%.

[0060] Example 5 The principle for preparing compound B3 is shown in Formula 4: Equation 4; B2 (200 g), sodium hydroxide (60.3 g), water (200 mL), and tetrahydrofuran (1 L) were added to a reaction vessel and stirred at room temperature until clear. Then, di-tert-butyl dicarbonate (411.3 g) was added and the reaction was carried out at 20 °C for 8 h. The mixture was diluted with 200 mL of water, and the pH was adjusted to 2.0 with 2 M hydrochloric acid. The aqueous phase was extracted with ethyl acetate (600 mL × 3 times), and the solvent was removed by rotary evaporation to obtain 304.5 g of pale yellow solid compound, which was methyl (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylate (compound B3), with a yield of 93.5%. 1 H NMR (400 MHz, DMSO- D 6 ) δ 4.20-4.16 (m, 1H), 3.96-3.81(m, 2H), 3.65-3.52 (m, 2H), 3.47-3.21 (m, 1H), 3.16 (s, 3H), 3.14-3.09 (m,1H), 1.73-1.66 (m, 2H), 1.40-1.38 (d, J = 6.0 Hz, 9H).

[0061] Figure 3 The above is the 1H NMR spectrum of compound B3 prepared in Example 5 of this invention.

[0062] Example 6 Preparation of compound B3: B2 (200 g), potassium hydroxide (103.6 g), water (300 mL), acetonitrile (2 L), and di-tert-butyl dicarbonate (548.4 g) were added to a reaction vessel and stirred at 10 °C for 10 h. The mixture was diluted with 200 mL of water, the pH was adjusted to 2 with 2 M hydrochloric acid, and the aqueous phase was extracted with ethyl acetate (600 mL × 3 times). The solvent was removed by rotary evaporation to obtain 296.9 g of a pale yellow solid compound, which was methyl (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylate (compound B3), with a yield of 91.2%.

[0063] Example 7 The principle for preparing compound B is shown in Formula 5: Formula 5; In a reaction vessel, a solution of sodium hydroxide (30.9 g) in water (400 mL) was added to a methanol (2 L) solution of B3 (200 g). The reaction mixture was heated to 70 °C and stirred for 7 h. After cooling to room temperature, the mixture was extracted with diethyl ether. The combined organic solutions were washed with brine, dried over sodium sulfate, and concentrated under vacuum to give a white solid crude product. The solid was recrystallized from hexane and dichloromethane (400 mL: 1 L) to give 183.7 g of a white solid, which was (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylic acid (compound B), with a yield of 97.0%. 1 H NMR (400 MHz, DMSO- D 6 ) δ 12.74 (s, 1H), 4.21-4.16 (m, 1H), 3.96-3.81 (m, 2H), 3.65-3.53 (m, 2H), 3.47-3.35 (m, 1H), 3.28-3.07 (m, 1H), 1.72-1.66 (m, 2H), 1.40-1.38 (d, J = 6.3 Hz, 9H).

[0064] Figure 4 The above is the 1H NMR spectrum of compound B prepared in Example 7 of this invention.

[0065] Example 8 Preparation of compound B: In a reaction vessel, a solution of lithium hydroxide (18.5 g) in water (400 mL) was added to a methanol (2 L) solution of B3 (200 g). The reaction mixture was heated to 60 °C and stirred for 10 h. After cooling to room temperature, the mixture was extracted with diethyl ether. The combined organic solutions were washed with brine, dried over sodium sulfate, and concentrated under vacuum to give a white solid crude product. The solid was recrystallized from hexane and dichloromethane (hexane to dichloromethane volume ratio 400 mL: 1 L) to give 178.6 g of a white solid, which was (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylic acid, in 94.5% yield.

[0066] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principles of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A method for preparing (S)-4-(tert-butoxycarbonyl)-1,4-oxazacycloheptane-2-carboxylic acid, characterized in that, Includes the following steps: (S)-isoserine was esterified with methanol in the presence of an acyl chloride to give compound B1. Under the action of a first alkaline reagent, compound B1 was subjected to a cyclization reaction with 1,3-dibromopropane in an organic solvent to obtain compound B2; In the presence of a second alkaline reagent, compound B2 is reacted with di-tert-butyl dicarbonate in an organic solvent to undergo an N-acylation reaction to obtain compound B3; Under the action of a third basic reagent, compound B3 was hydrolyzed in an organic solvent to obtain (S)-4-(tert-butoxycarbonyl)-1,4-oxazetane-2-carboxylic acid; The structural formulas of compounds B1, B2 and B3 are shown below: 、 、 。 2. The preparation method according to claim 1, characterized in that, The molar equivalent ratio of the acyl chloride reagent to (S)-isoserine is 1.2~1.8:

1.

3. The preparation method according to claim 1, characterized in that, The molar equivalent ratio of the first basic reagent to compound B1 is 3.0~5.0:

1.

4. The preparation method according to claim 1, characterized in that, The molar equivalent ratio of 1,3-dibromopropane to compound B1 is 1.2~1.5:

1.

5. The preparation method according to claim 1, characterized in that, The molar equivalent ratio of the second basic reagent to compound B2 is 1.2~1.5:

1.

6. The preparation method according to claim 1, characterized in that, The N-acylation reaction is carried out at a temperature of 0~30℃ for a time of 6~12h.

7. The preparation method according to claim 1, characterized in that, The molar equivalent ratio of the third basic reagent to compound B3 is 0.57~1.0:

1.

8. The preparation method according to claim 1, characterized in that, The organic solvents used in the hydrolysis reaction include one or more of tetrahydrofuran, acetonitrile, methanol, ethanol, isopropanol, acetone, and 1,4-dioxane.

9. The preparation method according to claim 1, characterized in that, The cyclization reaction is carried out at a temperature of 25-60°C for 10-20 hours.

10. The preparation method according to claim 1, characterized in that, The hydrolysis reaction is carried out at a temperature of 50-80℃ for 6-12 hours.